FluoGuide has received approval from the Danish Medicines Agency to initiate phase II trial with FG001 in head and neck cancer

Copenhagen, Denmark, 6 September 2022 – FluoGuide A/S (“FluoGuide” or the “Company”) is delighted to announce that the company has received approvals to initiate the phase II trial in head and neck cancer. The trial is expected to enrol first patient in Q4 2022.

The release as fetched from its publisher. fluoguide.com ↗